Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Share-based Compensation: 2023-2025

Historic Share-based Compensation for Camp4 Therapeutics (CAMP) over the last 2 years, with Sep 2025 value amounting to $984,000.

  • Camp4 Therapeutics' Share-based Compensation fell 38.19% to $984,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year decrease of 5.84%. This contributed to the annual value of $4.0 million for FY2024, which is 38.70% up from last year.
  • As of Q3 2025, Camp4 Therapeutics' Share-based Compensation stood at $984,000, which was down 1.80% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, Camp4 Therapeutics' Share-based Compensation ranged from a high of $1.6 million in Q3 2024 and a low of $636,000 during Q4 2023.
  • For the 3-year period, Camp4 Therapeutics' Share-based Compensation averaged around $915,111, with its median value being $856,000 (2024).
  • In the last 5 years, Camp4 Therapeutics' Share-based Compensation spiked by 120.50% in 2024 and then tumbled by 38.19% in 2025.
  • Over the past 3 years, Camp4 Therapeutics' Share-based Compensation (Quarterly) stood at $636,000 in 2023, then grew by 25.31% to $797,000 in 2024, then slumped by 38.19% to $984,000 in 2025.
  • Its Share-based Compensation was $984,000 in Q3 2025, compared to $1.0 million in Q2 2025 and $861,000 in Q1 2025.